Kronos Bio Inc expected to post a loss of 44 cents a share - Earnings Preview

Kronos Bio

28/04/2023 12:49

* Kronos Bio Inc  KRON.OQ   KRON.O  is expected to show a
rise in
quarterly revenue when it reports  results on May 2
(estimated). 
    * The San Mateo California-based  company is expected to
report
revenue of $5.625 million, according to the mean estimate from 4
analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Kronos Bio Inc is
for a
loss of 44 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Kronos Bio
Inc is
$10​, above​ its last closing price of $1.49. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.48       -0.59      -0.56     Beat    4.4
 Sep. 30 2022  -0.65       -0.65      -0.57     Beat    12.6
 Jun. 30 2022  -0.69       -0.69      -0.59     Beat    14.7​
 Mar. 31 2022  -0.65       -0.66      -0.65     Beat    1.2
 ​​Dec.        -1.08       -1.10      -1.13     Missed  -2.9
 31 2021                                                
 Sep. 30 2021  -0.99       -1.01      -0.61     Beat    39.7​
 Jun. 30 2021  -0.59       -0.62      -0.53     Beat    14.8
 Mar. 31 2021  -0.43       -0.43      -0.48     Missed  -10.7
 This summary was machine generated April 28 at 11:49 GMT.  All
figures in US dollars  unless otherwise stated